HPS Pharmacies wish to give notice that GlaxoSmithKline Australia are currently experiencing an interruption to the supply of:
This supply interruption is due to a temporary hold placed on the manufacturing and release of products from one of GlaxoSmithKline Australia’s facilities. Resultantly, there is a disruption to the supply of all strengths of Ultiva® vials. Once current supplies have been exhausted, normal supplies are not expected to resume until 2018.
Alternative brands of remifentanil are available. However, it is anticipated that these products may also experience supply issues during this time due to increased demand.
Further to DrugAlert Volume 281, DBL™ Remifentanil 1mg vials are currently unavailable. Normal supplies of this product are expected to resume in January 2017. Until this time, DBL™ Remifentanil 2mg vials may be used to deliver the appropriate dose.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies, or GlaxoSmithKline Australia on (03) 9721 8600.
Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.